TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04284813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRAFT-FT
Description: CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.
Study: NCT02983422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminophylline
Description: To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: frusemide
Description: Use frusemide with Syringe pumps,maximum dose to 15mg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: frusemide
Description: Use frusemide with Syringe pumps,maximum dose to 15mg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
Study: NCT03573479

Intervention type: OTHER
Intervention: PICU Liber8 Bundle
Description: Bundle of elements for quality improvement
Study: NCT01829581

Intervention type: OTHER
Intervention: no intervention, only descriptive data analysis
Study: NCT04425733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 administered at a dose of 180 µg or ≤360 µg QD via inhalation
Study: NCT03398603

Intervention type: PROCEDURE
Intervention: blood sample and ultrasound
Description: When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.

Intervention type: PROCEDURE
Intervention: blood sample and ultrasound
Description: When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.
Study: NCT04172597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Hydrochloride
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Hydrochloride
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Hydrochloride
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Hydrochloride
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Hydrochloride
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide as prescribed by the physician.
Study: NCT04172597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide as prescribed by the physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide as prescribed by the physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide as prescribed by the physician.
Study: NCT04172597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide as prescribed by the physician.
Study: NCT02685683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of \>50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI \<7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
Study: NCT04425733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-5475-matching placebo administered QD via inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-5475-matching placebo administered QD via inhalation
Study: NCT03437070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Administered intravenously per protocol on Day 1 for 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered intravenously per protocol on Day 1 for 21-day cycles.
Study: NCT04425733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-5475-matching placebo administered QD via inhalation
Study: NCT03414619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Tasks and Script Driven Imagery
Description: All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Tasks and Script Driven Imagery
Description: All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.
Study: NCT04460651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icosapent ethyl (IPE)
Description: Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
Study: NCT03437070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered intravenously per protocol
Study: NCT04460651

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
Study: NCT00819455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Active Life style modification-motivation by I.T technology
Study: NCT01820481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-901X dose level 1
Description: 100mg Bid, PO, 12weeks
Study: NCT04373967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Patients who were receiving metformin prior to study will continue to receive it during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Patients who were receiving metformin prior to study will continue to receive it during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQZ2451
Description: Patients will receive TQZ2451.Both products will be provided as pen-injector.
Study: NCT04002349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)
Description: Detailed in arm descriptions
Study: NCT01820481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-901X dose level 2
Description: 200mg Bid, PO, 12weeks
Study: NCT00756223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A
Description: Dose escalation Arm A (4 weeks)
Study: NCT00819455

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (usual care/standard care arm)
Description: Life style modification only once
Study: NCT04069923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium-based Bone Void Filler
Description: Given intraoperatively
Study: NCT03056963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Self-Reference Training
Description: Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Training Control
Description: Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
Study: NCT04340440

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D1 lymphadenectomy
Description: Radical gastrectomy with D1 lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 lymphadenectomy
Description: Radical gastrectomy with D2 lymphadenectomy
Study: NCT02089113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study: NCT01820481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-901X dose level 3
Description: 300mg Bid, PO, 12weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bid, PO, 12weeks
Study: NCT00167661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
Study: NCT03094559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowMet
Description: The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
Study: NCT00424268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 µg, once daily, oral administration in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT00739466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Alendronate
Description: IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Alendronate
Description: IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion (placebo)
Description: IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
Study: NCT04552327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solcera
Description: Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
Study: NCT00756223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B
Description: Dose escalation Arm B (3 weeks)
Study: NCT01880489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI + CBST Intervention
Description: The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
Study: NCT04327505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
Study: NCT01230021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
Study: NCT02798159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate 50mg
Study: NCT03480360

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 30 mg/m2 daily for 5 days

Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation
Description: 200 centigray (cGy) for one day (day -1)

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: 1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.

Intervention type: DRUG
Group type: OTHER
Intervention: cellcept
Description: dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.

Intervention type: DRUG
Group type: OTHER
Intervention: g-csf
Description: 5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \> 1000/mcL for 3 days.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral Blood Transplant
Description: cell dose goal: \< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
Study: NCT02365961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivicaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noropin
Study: NCT03627442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy with PhotonBlade
Description: One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy with Bovie
Description: One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
Study: NCT01475214

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: potassium bicarbonate
Description: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
Study: NCT04552327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solaraze
Description: Twice daily application for a duration of 60 days
Study: NCT01064687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Study: NCT03403075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ETAF
Description: Therapeutic education and Physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT03844256

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nivolumab 480mg
Description: Immuno-chemoradiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nivolumab 3mg/kg, ipilimumab 1mg/kg
Description: Immuno-chemoradiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nivolumab 1mg/kg, ipilimumab 3mg/kg
Description: Immuno-chemoradiotherapy
Study: NCT03860324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-shot erector spinae plane block
Description: Single-shot Erector Spinae Plane block with 30ml of ropivacaine 0,5% + adrenaline 150mcg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-shot fascia iliaca block
Description: Single-shot Fascia Iliaca block with 40ml of ropivacaine 0,2%
Study: NCT01515917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice bran oil
Description: Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
Study: NCT03608527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary-based upper limb motor rehabilitation
Description: Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive upper limb mobilization
Description: Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
Study: NCT01260701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study: NCT00208273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole - Concomitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole - Sequential
Study: NCT03917927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eztetic dental implant
Description: narrow diameter dental implant
Study: NCT02850731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plate-forme Hu360®
Description: the innovative technology (plate-forme Hu360®) will be used in the experimental arm